Publication in refereed journal
香港中文大学研究人员 ( 现职)
| 梁惠棠教授 (肿瘤学系) |
| 莫树锦教授 (肿瘤学系) |
全文
| 没有全文档案提供 |
引用次数
Scopushttp://aims.cuhk.edu.hk/converis/portal/Publication/4Scopus source URL
其它资讯
摘要Objective. To review the systemic chemotherapy regimens for pancreatic cancer. Data sources. Medline and non-Medline literature search (1966-1999). Study selection. The following key words were used: pancreatic carcinoma; chemotherapy; antineoplastic agent; fluorouracil; gemcitabine. Data extraction. Reports of phase II studies, randomised controlled studies, and preclinical studies were reviewed. Data synthesis. Less than 20% of patients are suitable candidates for surgery; for the reminder, palliative chemotherapy is of only marginal benefit. Combining fluorouracil with folinic acid or interferon has not led to any significant improvement in tumour response or the patient survival rate. The early encouraging results with combination chemotherapy have not been confirmed in subsequent controlled studies. New approaches include immunotherapy and novel cytotoxic drugs. In vitro studies of monoclonal antibodies have shown promise but have failed to show clinical efficacy. Recently, gemcitabine has been shown to be more effective than fluorouracil in delivering pain relief and reducing disease- related symptoms. Conclusions. Systemic chemotherapy is generally ineffective in increasing the survival time of patients with pancreatic cancer. Future clinical investigations concerning treatment should focus on gemcitabine- based combination chemotherapy or combined modality treatment with radiotherapy.
着者Mok T.S.K., Leung T.W.T.
期刊名称Hong Kong Medical Journal
出版年份1999
月份12
日期1
卷号5
期次http://aims.cuhk.edu.hk/converis/portal/Publication/4
出版社Hong Kong Academy of Medicine Press
出版地Hong Kong
页次367 - 37http://aims.cuhk.edu.hk/converis/portal/Publication/4
国际标準期刊号102http://aims.cuhk.edu.hk/converis/portal/Publication/4-2708
电子国际标準期刊号2226-8707
语言英式英语
关键词Antineoplastic agents/therapeutic use, Deoxycytidine/analogs and derivatives, Pancreatic neoplasms, Survival rate
